In an experimental model of Parkinson’s disease, catalpol increases the concentration of striatal dopamine and the level of glial cell-derived neurotrophic factor (GDNF) (Xu et al., 2010), thereby exerting its neuroprotective functions. Here, GDNF is linked to Parkinson disease.